PriceTargets.com logo

PMV Pharmaceuticals - PMVP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.80
  • Forecasted Upside: 286.67%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$1.50 As of 12/20/2024 06:30 PM ET
+0 (0.00%)

This chart shows the closing price for PMVP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PMV Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PMVP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PMVP

Analyst Price Target is $5.80
▲ +286.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for PMV Pharmaceuticals in the last 3 months. The average price target is $5.80, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 286.67% upside from the last price of $1.50.

This chart shows the closing price for PMVP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in PMV Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024OppenheimerUpgradeMarket Perform ➝ Outperform$6.00
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
5/13/2024CLSAUpgradeStrong-Buy
5/13/2024Craig HallumInitiated CoverageBuy$6.00
4/12/2024Jefferies Financial GroupInitiated CoverageBuy$5.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
12/27/2023LADENBURG THALM/SH SHInitiated CoverageBuy$7.00
10/16/2023HC WainwrightLower TargetBuy ➝ Buy$29.00 ➝ $5.00
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $29.00
3/20/2023HC WainwrightLower Target$36.00 ➝ $35.00
3/2/2023OppenheimerLower TargetOutperform$28.00 ➝ $15.00
11/17/2022HC WainwrightLower TargetBuy$63.00 ➝ $36.00
6/9/2022OppenheimerBoost TargetOutperform$30.00 ➝ $33.00
6/8/2022HC WainwrightReiterated RatingBuy$63.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$43.00 ➝ $25.00
3/2/2022OppenheimerUpgradeMarket Perform ➝ Outperform$30.00
11/15/2021HC WainwrightReiterated RatingBuy$62.00
9/22/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$35.00 ➝ $43.00
8/19/2021OppenheimerInitiated CoverageMarket Perform
8/2/2021GuggenheimInitiated CoverageBuy$56.00
7/29/2021HC WainwrightInitiated CoverageBuy$63.00
10/20/2020Evercore ISIInitiated CoverageOutperform
10/20/2020Bank of AmericaInitiated CoverageBuy$42.00
10/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$34.00
10/20/2020CowenInitiated CoverageOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.34 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PMV Pharmaceuticals logo
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $1.50
Low: $1.46
High: $1.51

50 Day Range

MA: $1.61
Low: $1.49
High: $1.78

52 Week Range

Now: $1.50
Low: $1.40
High: $3.47

Volume

233,712 shs

Average Volume

387,099 shs

Market Capitalization

$77.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of PMV Pharmaceuticals?

The following sell-side analysts have issued stock ratings on PMV Pharmaceuticals in the last year: CLSA, Craig Hallum, HC Wainwright, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, and Oppenheimer Holdings Inc..
View the latest analyst ratings for PMVP.

What is the current price target for PMV Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for PMV Pharmaceuticals in the last year. Their average twelve-month price target is $5.80, suggesting a possible upside of 286.7%. LADENBURG THALM/SH SH has the highest price target set, predicting PMVP will reach $7.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $5.00 for PMV Pharmaceuticals in the next year.
View the latest price targets for PMVP.

What is the current consensus analyst rating for PMV Pharmaceuticals?

PMV Pharmaceuticals currently has 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PMVP will outperform the market and that investors should add to their positions of PMV Pharmaceuticals.
View the latest ratings for PMVP.

What other companies compete with PMV Pharmaceuticals?

Other companies that are similar to PMV Pharmaceuticals include Jasper Therapeutics, Tango Therapeutics, Valneva, Immutep and 4D Molecular Therapeutics. Learn More about companies similar to PMV Pharmaceuticals.

How do I contact PMV Pharmaceuticals' investor relations team?

The company's listed phone number is 609-642-6670 and its investor relations email address is [email protected]. The official website for PMV Pharmaceuticals is www.pmvpharma.com. Learn More about contacing PMV Pharmaceuticals investor relations.